Village Farms (VFF) Q1 2026: International Medical Exports Surge 171%, Cementing EU GMP Advantage
Village Farms’ Q1 2026 results underscore the power of its international medical cannabis engine, with record export momentum and robust margin performance driven by EU GMP compliance. Strategic capacity expansion and disciplined capital allocation set the stage for durable profitability as the company navigates regulatory tailwinds and global market complexity. Investors should watch for execution on new form factors and international market entries as capacity ramps in the second half.
Summary
- International Medical Exports Drive Growth: Record EU GMP cannabis exports propel global share gains and margin strength.
- Disciplined Capital and Capacity Expansion: Delta II and Netherlands ramp-up position VFF for scale and flexibility in H2.
- Regulatory Tailwinds Shape U.S. and EU Strategy: Patient M&A posture and compliance focus signal prudent approach to emerging opportunities.
Business Overview
Village Farms International is a pure-play global cannabis producer, operating advanced greenhouse facilities focused on medical and adult-use cannabis markets. Revenue is generated through international medical exports—primarily to Germany and other EU countries—Canadian branded sales, and emerging operations in the Netherlands. The business now reports as a single global cannabis segment, reflecting its operational focus on EU GMP, good manufacturing practice, certified cannabis for export and domestic channels.
Performance Analysis
Q1 2026 marked a decisive shift for Village Farms, with consolidated net sales up 27% year over year, powered by a 171% leap in international medical exports. The German market was a standout, with VFF holding three of the top five cultivars and capturing increasing market share as regulatory enforcement tightened against non-compliant supply. The company’s Canadian branded sales grew modestly, supported by a continued pivot to higher margin products and a top-five national share, while the Netherlands business contributed a full quarter of sales compared to a partial quarter last year.
Profitability outpaced revenue growth, with adjusted EBITDA up 118% year over year and net income positive for the fourth consecutive quarter. Gross margin for Canada reached 43%, above the targeted 30-40% range, reflecting the benefit of international exports and product mix. The business absorbed a temporary drag from a large Canadian tax payment, resulting in negative Q1 operating cash flow, but management expects a return to positive cash generation from Q2 onward as new capacity comes online and working capital normalizes.
- Export Momentum: International sales, especially to Germany, remain the key growth engine and margin lever.
- Margin Expansion: Gross margin in Canada above historical range, underpinned by export mix and product shift.
- Cash Flow Dynamics: Q1 cash outflows from taxes and investments expected to reverse in Q2, supporting liquidity and flexibility.
Share repurchases and a manageable debt load further support a disciplined shareholder return framework, with over $6 million in shares repurchased and an extended debt maturity profile.
Executive Commentary
"The continued strength of our international medical business was once again a powerful driver of growth and profitability, with international export sales increasing 171% year over year and 60% sequentially to a record of nearly $15 million... Demand for our products continues to increase and our partners are increasingly seeking our EU GMP compliant product in the wake of stricter regulations and enforcement that are restricting the flow of non-compliant product in several jurisdictions."
Michael DiGilio, Chief Executive Officer
"We believe we are the only major Canadian cannabis LP in the position of paying corporate income taxes, which is a testament to the strength of our operating capabilities and strong stewardship of capital on behalf of our shareholders and a sign of a sustainable, long-term, profitable business platform."
Steve Ruffini, Chief Financial Officer
Strategic Positioning
1. EU GMP Compliance as a Competitive Moat
VFF’s early and sustained investment in EU GMP certification, which sets rigorous pharmaceutical-grade standards for cannabis production, has created a durable barrier to entry in international markets. The company now operates what it believes is the world’s largest EU GMP facility, enabling it to capture premium pricing and outsized share in Germany and other regulated markets.
2. Capacity Expansion in Canada and the Netherlands
The Delta II greenhouse expansion, expected to ramp to 40 metric tons annually by mid-2027, will increase British Columbia production capacity by 33%. This, along with the impending launch of the advanced Phase II facility in Groningen, Netherlands, positions VFF to meet rising demand and support form factor innovation as new jurisdictions open.
3. Disciplined M&A and Capital Allocation
Management’s posture toward M&A is notably cautious, emphasizing selectivity and patience amid regulatory ambiguity—especially in the U.S. The company is clear it will only pursue deals that are strategically and financially accretive, with CFO Steve Ruffini now leading this function to ensure alignment with long-term shareholder value creation.
4. Brand Leadership and Channel Focus in Canada
The PureSun Farms brand continues to extend its market share streak, now at 15 consecutive months of gains in dried flower. VFF remains committed to the branded channel, in contrast to some peers, and leverages consumer loyalty to defend and grow its position in the adult-use segment.
5. Operational Flexibility and Cost Leadership
Low-cost greenhouse production and supply chain investments enable VFF to deliver consistent, compliant product at scale, supporting both margin resilience and adaptability to shifting regulatory or market conditions.
Key Considerations
This quarter’s results and management commentary reflect a business operating from a position of strength, but also one acutely aware of the volatility and complexity in global cannabis markets. Execution on capacity expansion, regulatory navigation, and disciplined capital deployment remain central to the investment case.
Key Considerations:
- Export-Driven Margin Profile: International medical sales are higher margin and less exposed to price compression compared to domestic channels.
- Capacity Timing Risk: Delta II and Netherlands expansions are critical for meeting demand and driving scale benefits in H2 and beyond.
- Shareholder Alignment: Management and board remain closely aligned with shareholders, as evidenced by insider ownership and buybacks.
- Regulatory Optionality: U.S. rescheduling and EU market evolution present both upside and execution risk; VFF’s compliance-first approach provides flexibility.
Risks
Village Farms faces ongoing regulatory, market, and execution risk. Delays in capacity certification, shifts in export regulations, or unforeseen price compression in core markets could pressure near-term results. The company’s disciplined capital approach mitigates M&A missteps, but dependence on a few key export markets and evolving regulatory frameworks (notably in the U.S. and EU) create ongoing uncertainty. Management’s patient posture is prudent, yet requires flawless execution as capacity comes online.
Forward Outlook
For Q2 2026, Village Farms expects:
- Return to positive cash flow from operations as tax impacts normalize
- Initial sales contribution from Delta II expansion and Netherlands Phase II facility ramp-up
For full-year 2026, management maintained its outlook for continued profitable growth, citing:
- Visibility on stable international pricing and rising demand for EU GMP product
- Ongoing expansion into new international jurisdictions and form factors
Leadership highlighted confidence in capacity-driven sales acceleration in the back half of the year, with regulatory developments in the U.S. and EU as key watchpoints.
- Delta II and Netherlands facilities expected to drive scale and flexibility
- Disciplined approach to U.S. and global M&A as regulatory clarity emerges
Takeaways
Village Farms is proving the value of a compliance-first, export-driven cannabis strategy, with international medical sales and cost leadership anchoring both growth and profitability. The company’s patient approach to capital deployment and regulatory navigation sets it apart in a sector often marked by overreach and volatility.
- Export Engine: Record international sales and pricing stability demonstrate the payoff from years of EU GMP investment and operational discipline.
- Disciplined Expansion: Capacity growth in Canada and the Netherlands is set to unlock further scale and margin benefits, but execution risk remains as new facilities ramp.
- Regulatory Optionality: U.S. rescheduling and new market entries could provide upside, but management’s measured approach will prioritize long-term value over near-term headlines.
Conclusion
Village Farms’ Q1 2026 results highlight a global cannabis platform firing on all cylinders, with international medical exports, cost leadership, and capacity expansion forming the backbone of its growth story. As regulatory tailwinds and operational milestones converge in the second half, the company remains a standout for its strategic discipline and margin resilience.
Industry Read-Through
VFF’s success in international medical cannabis exports and EU GMP compliance signals a clear industry shift toward higher regulatory standards and premiumization in global markets. The tightening of enforcement in Germany and other EU countries is likely to favor scale players with compliant infrastructure, while smaller or less rigorous operators may face margin compression or exclusion. The cautious, value-focused approach to M&A and capital allocation is a template for other cannabis companies seeking durable profitability and investor trust. U.S. regulatory developments remain the wildcard, but operators with proven compliance and export readiness are best positioned to capitalize on cross-border opportunities as they emerge.